SUMMARY Five commercial kits for the determination of folate and six kits for the determination of vitamin B12 were investigated. Their performance has been compared with microbiological methods for the two vitamins and with a non-commercial radioisotopic method for B12. The results show the importance of the determination of the reference range for an individual laboratory for each method. The precision of the kits varied appreciably, as did their performance using specimens from patients with different haematological disorders. In particular, certain kits failed to detect all patients with pernicious anaemia. The relative accuracy of the kits was assessed. Various factors which should be taken into account in the final selection of a satisfactory kit are discussed. 
In recent years, several commercial firms have introduced isotopic systems for the assay of folate and vitamin B12. Their apparent ease of use has led to an increasing number of laboratories turning to them before their merits and demerits have been fully determined. At the end of 1977 the Laboratory and Development Advisory Group of the Department of Health and Social Security asked us to assess the kits available in the United Kingdom. Our full report was submitted in May 1979 to the Group. This paper lists the kits tested and summarises the procedures used and the findings obtained.
Material and methods

COMMERCIAL KITS
The kits investigated and their abbreviations are listed in Table 1. NON-COMMERCIAL B12 RADIOASSAY METHOD (NCM) The NCM for B12 was that of Matthews et al.1
MICROBIOLOGICAL METHODS (MM) The microbiological method used for the assay of folate was that of Davis et al.2
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CONTROL MATERIALS
These consisted of Ortho RIA control sera I and II; pteroylglutamic acid (PGA) and N-5 methyl tetrahydrofolic acid (methyl THF) from Sigma London Chemical Co; Cyanocobalamin Injection BP of certified potency obtained from Glaxo Laboratories Ltd; 10 human serum pools of varying vitamin concentration and for AM B12 the control samples provided with this kit.
REFERENCE AND CLINICAL SAMPLES
Reference samples were collected from 80 Within-batch precision was based on the duplicates of the reference population. Between-batch precision was based on the variation between the means of the duplicates of serum samples assayed weekly throughout the duration of the trial. Accuracy was assessed from the results obtained for aqueous analyte assays, recovery of added vitamin, and correlation with the comparative methods. Shelf-life was studied by comparing pairs of results from assays done with kits at the beginning and at a later stage in their stated shelf-life. Reconstituted reagents were tested similarly after storage according to the manufacturer's recommendations.
ASSAY COMPOSITION
The assays were performed using three different batches of each kit. All samples were tested in duplicate except for the folate microbiological methods which had to be done singly because of a national shortage of assay medium at the time of the trial. (Table 4) , and recovery of both vitamins was disappointing (Table 5) . Correlation between methods is illustrated in Table 6 , which summarises regression analysis for all methods and is derived from log scores for reference and clinical samples combined. Folate deficiency (7 patients) There was no overlap between the results in this group and pernicious anaemia with any kit except AM.
Iron deficiency (8 patients) The majority of results were below the mean of the reference ranges, and there was generally agreement between the kits.
Myeloproliferative disease (5 chronic myeloid leukaemia, I polycythaemia rubra vera) All results, except one by QM, were above the reference range.
SUBJECTIVE ASSESSMENT AND COSTING
The results are shown in 
Discussion
The selection of any analytical method requires consideration of several aspects, and it is not often that one particular method excels in all these so that the ultimate choice is a matter of judgement as to the relative importance of good and bad points. In order to evaluate the clinical usefulness of a method it is essential to establish a reference range. The 95 % reference ranges that we obtained varied considerably between methods, presumably reflecting differing accuracies. They also varied somewhat from those proposed by the manufacturers. Even with our criteria for selection, the residual apparently healthy population could still include cases of subclinical folate deficiency. With QCT and BD, our ranges for B12 are rather higher, and for QM lower, than those of the manufacturers, suggesting that the reference population used is a reasonably typical one. These points emphasise the need to determine independent reference ranges. Throughout the evaluation, samples from the reference population and from the patients were assayed in parallel to allow direct comparison of results.
Our precision measurements were more comprehensive than those usually employed and are more likely to reflect the actual conditions in the laboratory for which the kits are intended. The precision attained by the majority of methods was worse than the CV of 10% usually achievable by radioisotope assays.
The within-batch precision of folate assays was disappointing at low levels, QM, QCT, and BD giving acceptable results, whereas, probably owing to technical difficulties encountered with their use, SIM and AM did not. The AM kit has been reported to give CVs from 4 to 17 %34 and other l251-labelled folate kits CVs from 1-6 to 13.8%.5,6 The withinbatch precision for B12 assays was more satisfactory, all except SIM and MM giving acceptable results with the reference population. Our findings for PH were similar to the CV of 6 3 % achieved by Raven and Robson.7 Between-batch precision for serum folate was less satisfactory than was hoped for. The CV was worse at the lower end of the normal range but fell with increasing concentration, although the whole range was covered for only SIM, QM, and QCT. The best performance at the lower end of the reference ranges was a CV of about 30% for AM and MM, but extrapolation from the results suggests that this will fall below 10% at concentrations above 7 tkg/l.
No other kit seems likely to achieve the figure of 10% at any concentration. Published data for folate kits from this same group of manufacturers have yielded somewhat lower between-batch CVs than ours, but these are based on small samples over shorter times; figures vary between 6-6 and 15 % over the concentration range 3-4-10 tkg/1.3,6'8 For B12
assays, between-batch precision was better than for folate and, in particular, the CVs for AM and QCT remained below 10% over the whole of the reference range. PH gave the next most consistent performance, and our figures are similar to those of Raven Whitehead, 10 false results are connected with less severe degrees of anaemia. Our six patients with an incorrect result had a mean haemoglobin of 11-0 g/dl compared with 9.2 g/dl in the others. In myeloproliferative disorders all kits gave higher B12 levels than MM.
When the analytical and clinical performance are considered together it appears that, of the various kits for folate determination, the best combination is given by QM and QCT. Patients known to be on antibiotics were excluded from our study, but no important discrepancies attributable to them were found in the few cases in whom later investigation revealed that such therapy had been given. 
